PTGS2 and Alzheimer disease: AD patients show increased concentration of PGE2 in the cerebrospinal fluid and upregulated cyclooxygenase-2 (COX-2) in the brain; moreover, the deletion of PGE2 receptors result in neuroprotective effects in mouse models of AD [90,91].